Abstract

Background and Objectives: Scant data regarding early post-COVID-19 effects are available, especially in younger people. Therefore, the objective of this study was to explore the early clinical impacts of post-COVID-19 pneumonia, comparing severe and non-severe patients. Materials and Methods: A cross-sectional study was conducted in adult patients admitted with COVID-19 pneumonia from April to May 2021. Demographic data, symptoms and signs, quality of life, Hospital Anxiety and Depression Scale (HADS), chest radiograph (CXR), pulmonary function tests (spirometry, impulse oscillometry), fractional exhaled nitric oxide (FeNO), and exercise capacity were assessed one month after hospital discharge. Twenty-five healthy control subjects that were age- and gender-matched were recruited for comparisons. Results: One hundred and five patients, with a mean age of 35.6 ± 15.8 years and 54 (51.4%) males, participated and were categorized into the non-severe pneumonia (N = 68) and severe pneumonia groups (N = 37). At a one-month follow-up visit (the time from the onset of the disease symptoms = 45.4 ± 5.9 days), the severe group had more cough, fatigue, and skin rash with higher dyspnea scale, more residual CXR lesions, and lower quality of life scores. Forced vital capacity (FVC) was lower in the severe group (88.3% of predicted value) and non-severe group (94.6% of predicted value) than in the healthy controls (p = 0.001). The six-minute walk distance was significantly lower in the non-severe group, at 79.2 m, and in the severe group, at 103.8 m, than in the healthy control subjects (p < 0.001). Conclusions: Adult patients with COVID-19, especially those with clinically severe pneumonia, still had residual symptoms and chest radiographic abnormalities, together with poorer quality of life and lower exercise capacity, one month after hospital discharge.

Highlights

  • This article is an open access articleOn 31 December 2019, cases of pneumonia caused by novel coronavirus SARS-CoV-2(COVID-19 pneumonia) were reported from Wuhan city Hubei Province of China [1].This virus outbreak spread to other countries, affecting nearly 200 million people, and was responsible for over 4 million deaths worldwide as of July 2021 [2]

  • During the phase 3 (April–May 2021) outbreak of COVID-19 in Chiang Mai, 193 patients with COVID-19 pneumonia were admitted to our hospital and ten patients (5.2%) died during hospitalization

  • These patients were categorized into two groups: the non-severe pneumonia group, N = 68, and severe pneumonia group, N = 37 (pneumonia treated with high-flow nasal cannula oxygen (HFNC), N = 35, or mechanical ventilator, N = 2)

Read more

Summary

Introduction

This article is an open access articleOn 31 December 2019, cases of pneumonia caused by novel coronavirus SARS-CoV-2(COVID-19 pneumonia) were reported from Wuhan city Hubei Province of China [1].This virus outbreak spread to other countries, affecting nearly 200 million people, and was responsible for over 4 million deaths worldwide as of July 2021 [2]. On 31 December 2019, cases of pneumonia caused by novel coronavirus SARS-CoV-2. (COVID-19 pneumonia) were reported from Wuhan city Hubei Province of China [1]. This virus outbreak spread to other countries, affecting nearly 200 million people, and was responsible for over 4 million deaths worldwide as of July 2021 [2]. In Thailand, 597,287 people were infected, and 4857 people died by the end of July 2021 [3]. 2021, phase 3 of the COVID-19 outbreak began in Chiang Mai, Thailand, especially among young adults, and infected more than one hundred people per day. At the end of May 2021, there were 4068 cases of COVID-19 in Chiang Mai [3].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.